{'fraction_non_alphanumeric': 0.02131782945736434, 'fraction_numerical': 0.003875968992248062, 'mean_word_length': 5.154761904761905, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Safety of secukinumab in hepatitis B virus

The usage of TNF antagonists in patients with hepatitis B virus (HBV) can result in viral reactivation and potential liver failure. However, little is known about the risk of viral reactivation with the newer IL-17 antagonists. We report a patient with seropositive hepatitis B, ankylosing spondylitis, and disabling palmar plantar psoriasis treated successfully with secukinumab without liver complications. 
 
This article is protected by copyright. All rights reserved.